Mind Medicine (MindMed) Inc. announced that it has completed enrollment of Study MMED007, the Company's Phase 2a study evaluating repeated low-dose administration of MM-120 (lysergide D-tartrate) for the treatment of adults with ADHD. MMED007 is a multi-center, randomized, double-blind, placebo-controlled Phase 2a study of MM-120 (20 mg) compared with a placebo administered orally twice weekly for 6 weeks in adults between the ages of 18 and 65 with ADHD.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.26 USD | +1.54% | -7.40% | +153.01% |
May. 08 | Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024 | |
May. 08 | Mind Medicine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+153.01% | 666M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- MNMD Stock
- News Mind Medicine (MindMed) Inc.
- Mind Medicine Inc. Completes Enrollment of Phase 2A Trial of Mm-120 in Adults with Attention-Deficit/Hyperactivity Disorder